
Novocure’s device for metastatic NSCLC treatment gains CE Mark
Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC) simultaneously with immune checkpoint inhibitors or docetaxel. This offers a new option for those who have advanced on or …